<DOC>
	<DOC>NCT02141399</DOC>
	<brief_summary>This is a 52-week open-label study to evaluate the safety and tolerability of ALKS 5461.</brief_summary>
	<brief_title>A Long-Term Safety Study of ALKS 5461</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Agree to use an approved method of contraception for the duration of the study Have the potential to safely benefit from the administration of ALKS 5461 Have a diagnosis of major depressive disorder (MDD) Additional criteria may apply Have a positive test for drugs of abuse Currently pregnant or breastfeeding Have a current primary AxisI disorder other than MDD Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days Have received electroconvulsive therapy treatment within the last 2 years, or received more than 1 course of electroconvulsive treatment during their lifetime Have attempted suicide within the past 2 years Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone) Have had a significant blood loss or blood donation within the past 60 days Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>